Surgical options after Fontan failure

Joost P van Melle,1 Djoeeke Wolff,2 Jürgen Hörer,3 Emre Belli,4 Bart Meyns,5 Massimo Padalino,6 Harald Lindberg,7 Jeffrey P Jacobs,8,9 Ilkka P Mattila,10 Håkan Berggren,11 Rolf M F Berger,12 Rene Prêtre,12 Mark G Hazekamp,13,14 Morten Helvind,15 Matej Nosáľ,16 Tomas Tlaskal,17 Jean Rubay,18 Stojan Lazarov,19 Alexander Kadner,20 Viktor Hraska,21 José Fragata,22 Marco Pozzi,23 George Sarris,24,25 Guido Michielon,26 Duccio di Carlo,27 Tjark Ebels26

ABSTRACT
Objective The objective of this European multicenter study was to report surgical outcomes of Fontan takedown, Fontan conversion and heart transplantation (HTX) for failing Fontan patients in terms of all-cause mortality and (re-)HTX.

Methods A retrospective international study was conducted by the European Congenital Heart Surgeons Association across 22 member centres. Outcome of surgery to address failing Fontan was collected in 225 patients among which were patients with Fontan takedown (n=38; 17%), Fontan conversion (n=137; 61%) or HTX (n=50; 22%).

Results The most prevalent indication for failing Fontan surgery was arrhythmia (43.6%), but indications differed across the surgical groups (p<0.001). Fontan takedown was mostly performed in the early postoperative phase after Fontan completion, while Fontan conversion and HTX were mainly treatment options for late failure. Early (30 days) mortality was high for Fontan takedown (ie, 26%). Median follow-up was 5.9 years (range 0–23.7 years). The combined end point mortality/HTX was reached in 44.7% of the Fontan takedown patients, in 26.3% of the Fontan conversion patients and in 34.0% of the HTX patients, respectively (log rank p=0.08). Survival analysis showed no difference between Fontan conversion and HTX (p=0.13), but their ventricular function differed significantly. In patients who underwent Fontan conversion or HTX ventricular systolic dysfunction appeared to be the strongest predictor of mortality or (re-)HTX. Patients with valveless atrio pulmonary connection (APC) take more advantage of Fontan conversion than patients with a valve-containing APC (p=0.04).

Conclusions Takedown surgery for failing Fontan is mostly performed in the early postoperative phase, with a high risk of mortality. There is no difference in survival after Fontan conversion or HTX.

INTRODUCTION
For patients with various forms of functional univentricular congenital heart defects (CHD), a direct routing of the systemic return to the pulmonary arteries, in the absence of a pulmonary cardiac chamber, has been adopted as the usual surgical option. Since its invention, independently by both Fontan and Baudet1 and Kreutzer et al2 in 1971 and 1973 in France and Argentina, respectively, a large series of surgical improvements and refinements have resulted in a better outcome for these patients.3 Nowadays, it can be estimated that about 2.3:10 000 newborns with CHD are evaluated for the staged Fontan pathway, and of these, the majority reach adulthood.4 However, a growing body of evidence reveals that life-threatening complications inevitably occur from adolescence onwards. Therefore, the term ‘Failing Fontan’ has been introduced to refer to a clinical situation with major rhythm disturbances refractory to maximal medical therapy, thrombotic events in the Fontan circuit, protein losing enteropathy (PLE), plastic bronchitis, chronic oedema and ascites, cirrhosis and hepatic malignancy5 or ventricular failure.6 7 The surgical solutions for patients with failing Fontan have evolved over time. Nowadays, three surgical options are embraced worldwide: Fontan takedown,3 Fontan conversion to an energetically more favourable connection (ie, lateral tunnel (LT)9 or extracardiac conduit16) and heart transplantation11 12 (HTX). These high-risk procedures have been advocated based on institutional experience with limited data and non-uniform midterm results. The objective of this international multicenter study is to perform a comprehensive analysis of the midterm surgical outcome for failing Fontan surgery, in order to suggest an effective decision-making process for this growing subset of critically ill patients.

METHODS
Patients Patients who underwent Fontan surgery between 1971 and 31 December 2012 for the clinical syndrome of ‘Failing Fontan’ were eligible for inclusion in the F2 study. Three surgical options were taken into account: (1) Fontan takedown, (2) Fontan conversion and (3) HTX. Fontan takedown was defined as a takedown of a completed Fontan circulation to a superior cavopulmonary connection (bidirectional Glenn (BDG)) or a systemic-to-pulmonary arterial shunt (eg, Blalock–Taussig shunt) or both. Fontan conversion included a conversion from a traditional Fontan circulation (eg, an atrio pulmonary connection (APC) with or without valve, or a Björk modification) to a LT or extracardiac conduit (EC), and conversion from a LT to an EC. Revisions (ie, major surgery to modify a
suboptimal Fontan circuit without complete Fontan conversion) were excluded from analysis. Patients were identified within participating units of the European Congenital Heart Surgeons Association, with the use of local registries searching for Fontan patients or reviews of hospital patient charts. The University Medical Center Groningen coordinated the study, collected the data, maintained the database and performed all the data analyses. Review of medical records was approved by each local committee on clinical investigation. Individual patients were not identifiable, and the need for patient consent was waived.

Patient variables
The collected data on patient characteristics included primary anatomical diagnosis, relevant cardiovascular comorbidity, surgical interventions before the initial Fontan procedure, important prognostic patient variables previously described in Fontan research, that is, New York Heart Association (NYHA) functional class (FC)14 and cardiac function (ie, systolic ventricular function14 and atrioventricular valve regurgitation15) and preoperative cardiac medication use. Furthermore, the indications which led to failing Fontan surgery were classified as deteriorating FC, refractoriness of arrhythmia treatment, thrombus/emboli, severe right atrial (RA) dilatation, hemodynamic important obstruction in Fontan circuit, pulmonary venous obstruction, PLE, atrioventricular valve surgery, Fontan baffle leak or subaortic stenosis. More than one indication was possible within the same patient. Hemodynamic data (ie, RA pressure) from latest heart catheterisation were available for 170 patients. Finally, the following variables regarding failing Fontan surgery were documented: aortic cross clamp time, cardiopulmonary bypass time, duration of circulatory arrest, concomitant surgical interventions and postoperative duration of mechanical ventilation as well as hospital stay. Ventricular assist devices as a bridge to transplant were documented.

Statistical analysis
Data were analysed with the use of SPSS V20.0 for Windows. Continuous data were reported as mean±SD or median (IQR) and categorical data as number of patients (percentage of total, within the surgical arm). The primary end point was all-cause mortality or (re-)HTX. Secondary outcomes included early mortality (within 30 days of failing Fontan surgery) and late mortality. The last follow-up ended at 1 January 2014. Patients’ data were censored at the time of last contact. When appropriate, the primary end point was analysed according to the intention-to-treat principle. Thus, patients with a cross-over in surgical strategy (eg, Fontan conversion and during follow-up HTX) were analysed according to their initial intervention.

Baseline characteristics across the three groups were compared using one-way analysis of variance or χ² analyses, depending on the variable of interest. For other comparisons, the Student’s t test for continuous measures and the χ² test (or Fisher’s exact test) for categorical measures were used. Unadjusted survival rates and survival curves were determined by Kaplan–Meier estimates. The univariate and multivariate risk analyses of mortality/HTX were performed using time-dependent Cox proportional hazards models. For these survival and risk analyses, patients with a Fontan takedown were excluded. A two-sided p value <0.05 was considered to indicate statistical significance.

RESULTS
Two hundred twenty-five patients met the inclusion criteria (figure 1). They were identified from 22 congenital heart centres (range 1–40 patients/centre). Failing Fontan surgery took place in the time era 1986–2012. See tables 1 and 2 for the baseline characteristics. Patients were on average aged 5.9 ±4.9 years when they either had Fontan completion or had a one-stage Fontan procedure. In total, 136 patients (60.4%) had some form of APC, whereas the remainder had a total cavopulmonary connection (TCPC) (n=89; 39.6%).

In absolute counts, the most prevalent indication was arrhythmia (98/225 patients=43.6%, table 3). For 78 patients (34.7%), the decision for surgery was based on only one indication. However, for the whole population, the combination of 2.0 ±0.97 indications led to failing Fontan surgery. Arrhythmia and RA dilatation were the main indications for Fontan conversion, while deteriorating FC and PLE were the main indications for HTX (p <0.001, figure 2).

Failing Fontan surgery
Fontan takedown was performed in 38 patients (17%), Fontan conversion in 137 patients (61%, ie, 13% conversion to a TCPC LI and 48% to a TCPC EC) and HTX in 50 patients (22%). Two patients were successfully bridged to HTX by a paracorporeal ventricular assist device. Of all patients treated with Fontan conversion, 51.6% had concomitant rhythm surgery (maze rhythm surgery). The cumulative occurrence of surgical interventions for failing Fontan increased over time (p=0.01, see online supplementary figure S1). Yet, the distribution across the surgical groups did not change during the decades (p=0.19, see online supplementary figure S2).

The time interval between the initial Fontan procedure and the failing Fontan surgery was significantly shorter in the group referred for a Fontan takedown procedure (0.6±1.9 years) compared with patients who underwent HTX or Fontan conversion (8.5±6.1 years and 15.2±7.0 years, respectively; p<0.001). Comparison of the three groups also revealed statistical differences for the following variables: primary diagnosis, the presence of heterotaxy, previous BDG, type of initial Fontan surgery, preoperative NYHA class, ventricular dysfunction, atrial rhythm disturbances, RA pressure, age at failing Fontan surgery, extracorporeal circulation time, ventilation time, intensive care unit stay, hospital stay and medication use (tables 1 and 2).

Follow-up after Fontan takedown
During a mean follow up (FU) of 6.7±6.7 years (range 0–23.7 years), 15 patients (39.5%) died, of whom two-thirds (10/15 patients) in the first 30 postoperative days (ie, early mortality was 26.3%). After a mean period of 12.9±21.1 months, four patients (10.5%) underwent HTX after Fontan takedown with two patients alive at the end of follow-up. Two takedown patients (5.3%) underwent subsequent TCPC LI operation after a mean period of 34.1±14.1 months. A total of 17 patients (44.7%) had reached the primary end point mortality/HTX at the end of follow-up (see online supplementary figure S3).

Follow-up after Fontan conversion
During a mean FU of 7.7±5.7 years (range 0–24.7 years), a total of 30 patients died (21.9%). Thirty-six patients (26.3%) reached the combined end point mortality/HTX. Early mortality was 15/137 (10.9%). In seven patients (5.2%), the Fontan conversion was followed by HTX after a mean period of 3.3 ±2.8 years. One of these seven patients died 19.1 years after HTX. The primary end point mortality/HTX (n=36) occurred during 1000 patient-years follow-up (event rate 3.6/100 patient-years). Among the patients who survived Fontan conversion, 89% were in NYHA class I or II.

Within the 130 patients with an APC, patients with valveless APCs (n=89) had better outcomes after Fontan conversion than those with a valve-containing APC (n=41; p=0.04, figure 3). However, patients in the latter group were on average 3.7±1.8 years older (p=0.04). Event-free survival after Fontan conversion combined with MAZE rhythm surgery (n=64; 51.6%) did not significantly differ from Fontan conversion without rhythm surgery (n=60; 48.4%; p=0.57).

Follow-up after HTX
During a mean FU of 5.7±5.4 years (range: 0–22.2 years), 17 patients (34%) died. No patients underwent retransplantation. The mortality end point occurred during 287 patient-years follow-up (event rate 5.9/100 patient-years). Early mortality was 14% and in-hospital mortality was 20%. Of all patients who underwent failing Fontan surgery, HTX patients had the longest extracorporeal circulation time (289±169 min) and hospital

---

**Table 1** Baseline characteristics: demographics and medical history

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>All (n=225)</th>
<th>Conversion (n=137)</th>
<th>Takedown (n=38)</th>
<th>HTX (n=50)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male sex, N (%)</td>
<td>118 (52.4)</td>
<td>69 (50.4)</td>
<td>18 (47.4)</td>
<td>31 (62.0)</td>
<td>0.29</td>
</tr>
<tr>
<td>Diagnosis, N (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Tricuspid atresia</td>
<td>85 (37.8)</td>
<td>71 (51.8)</td>
<td>6 (15.8)</td>
<td>8 (16.0)</td>
<td></td>
</tr>
<tr>
<td>DILV</td>
<td>46 (20.4)</td>
<td>30 (21.9)</td>
<td>6 (15.8)</td>
<td>10 (20.0)</td>
<td></td>
</tr>
<tr>
<td>Unbalanced (AVSD)</td>
<td>21 (9.3)</td>
<td>5 (3.6)</td>
<td>10 (26.3)</td>
<td>4 (8.0)</td>
<td></td>
</tr>
<tr>
<td>HLHS</td>
<td>17 (7.6)</td>
<td>2 (1.5)</td>
<td>4 (10.5)</td>
<td>11 (22.0)</td>
<td></td>
</tr>
<tr>
<td>PA/IVS</td>
<td>17 (7.6)</td>
<td>11 (8.0)</td>
<td>2 (5.3)</td>
<td>4 (8.0)</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>39 (17.3)</td>
<td>18 (13.1)</td>
<td>10 (26.3)</td>
<td>11 (22.0)</td>
<td></td>
</tr>
<tr>
<td>Heterotaxy, N (%)</td>
<td>38 (16.9)</td>
<td>15 (10.9)</td>
<td>13 (34.2)</td>
<td>10 (20.0)</td>
<td>0.003</td>
</tr>
<tr>
<td>Pulmonary artery banding</td>
<td>47 (20.9)</td>
<td>25 (18.2)</td>
<td>11 (28.9)</td>
<td>11 (22.0)</td>
<td>0.35</td>
</tr>
<tr>
<td>Blalock-Taussig shunt</td>
<td>131 (58.2)</td>
<td>78 (56.9)</td>
<td>23 (60.5)</td>
<td>30 (60.0)</td>
<td>0.89</td>
</tr>
<tr>
<td>Bidirectional Glenn</td>
<td>72 (32.0)</td>
<td>13 (9.5)</td>
<td>26 (68.4)</td>
<td>33 (66.0)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Age at initial Fontan, years (±SD)</td>
<td>5.9 (4.9)</td>
<td>6.2 (4.8)</td>
<td>4.6 (2.9)</td>
<td>6.2 (6.1)</td>
<td>0.18</td>
</tr>
<tr>
<td>Type of initial Fontan surgery, N (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Björk modification</td>
<td>19 (8.4)</td>
<td>18 (13.1)</td>
<td>0 (0.0)</td>
<td>1 (2.0)</td>
<td></td>
</tr>
<tr>
<td>APC without valve</td>
<td>94 (41.8)</td>
<td>81 (59.1)</td>
<td>5 (13.2)</td>
<td>8 (16.0)</td>
<td></td>
</tr>
<tr>
<td>APC with valve</td>
<td>23 (10.2)</td>
<td>20 (14.6)</td>
<td>1 (2.6)</td>
<td>2 (4.0)</td>
<td></td>
</tr>
<tr>
<td>TCPC LT</td>
<td>45 (20.0)</td>
<td>18 (13.1)</td>
<td>12 (31.6)</td>
<td>15 (30.0)</td>
<td></td>
</tr>
<tr>
<td>TCPC EC</td>
<td>44 (19.6)</td>
<td>0 (0.0)</td>
<td>20 (52.6)</td>
<td>24 (48.0)</td>
<td></td>
</tr>
</tbody>
</table>

(AVSD, (atrio)ventricular septum defect; APC, atriopulmonary connection; DILV, double inlet left ventricle; EC, extracardiac conduit; HLHS, hypoplastic left heart syndrome; HTX, heart transplantation; LT, lateral tunnel; PA/IVS, pulmonary atresia with intact ventricular septum; TCPC, total cavopulmonary connection.)

---

*Figure 1* Flowchart describing the surgical treatment for patients with failing Fontan (n=231). HTX, heart transplantation; LT, lateral tunnel; EC, extracardiac conduit.
stay (43.0±46.7 days). Among the patients who were discharged from the hospital (n=43), 85% were in NYHA class I or II at the end of follow-up.

Risk analyses for mortality/HTX after failing Fontan surgery
Mean follow-up after HTX or Fontan conversion was 6.9 ±5.4 years. In only 15 patients, the follow-up duration exceeded 15 years and for that reason the unadjusted survival curve was truncated at 15 years after failing Fontan surgery. Although the survival curves diverge in favour of FC patients, event-free survival was not statistically different (p=0.13, figure 4).

Among the 187 patients with either a Fontan conversion or HTX, the following characteristics were significantly associated with the primary end point: time interval between initial Fontan surgery and failing Fontan (ie, more events in patients whose circulation start to fail within 10 years after initial Fontan), NYHA class III/IV and ventricular dysfunction (table 4). Multivariate analyses showed that patients with ventricular dysfunction have an increased risk of mortality/HTX (p=0.009).

Within the group of Fontan patients with an APC, no specific treatment benefit could be determined after 15 years follow-up between FC and HTX (p=0.80).

DISCUSSION
This multicenter, European observational study of failing Fontan patients is, to our knowledge, the largest in the world permitting analysis to compare different surgical strategies for a failing Fontan. We have shown that Fontan takedown has been used as a surgical strategy in the early postoperative phase after Fontan completion, whereas Fontan conversion or HTX were the most important surgical options in the long run. In

<table>
<thead>
<tr>
<th>Table 2</th>
<th>Preoperative and surgical variables (failing Fontan surgery)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Characteristic</td>
<td>All (n=225)</td>
</tr>
<tr>
<td>Age at failing Fontan surgery, years (±SD)</td>
<td>17.1 (10.3)</td>
</tr>
<tr>
<td>Time between Fontan completion and failing Fontan surgery, years (±SD)</td>
<td>11.2 (8.3)</td>
</tr>
<tr>
<td>NYHA class III/IV*, N (%)</td>
<td>112 (55.2)</td>
</tr>
<tr>
<td>≥Moderate AVV regurgitation, N (%)</td>
<td>55 (24.4)</td>
</tr>
<tr>
<td>Moderate/poor LV function, N (%)</td>
<td>115 (51.1)</td>
</tr>
<tr>
<td>Atrial rhythm disturbances, N (%)</td>
<td>112 (49.8)</td>
</tr>
<tr>
<td>RA pressure, mm Hg (±SD)</td>
<td>14.8 (4.3)</td>
</tr>
<tr>
<td>Medication use, N (%)</td>
<td></td>
</tr>
<tr>
<td>Aspirin</td>
<td>67 (29.8)</td>
</tr>
<tr>
<td>Coumadin</td>
<td>117 (52.0)</td>
</tr>
<tr>
<td>ACE-inhibitor</td>
<td>90 (40.0)</td>
</tr>
<tr>
<td>ß-Blocker</td>
<td>43 (19.1)</td>
</tr>
<tr>
<td>Digoxin</td>
<td>56 (24.9)</td>
</tr>
<tr>
<td>Sotalol</td>
<td>29 (12.9)</td>
</tr>
<tr>
<td>Amiodarone</td>
<td>47 (20.9)</td>
</tr>
<tr>
<td>ECC time, min (±SD)</td>
<td>197 (119)</td>
</tr>
<tr>
<td>Ventilation time, days (±SD)</td>
<td>5.4 (11.7)</td>
</tr>
<tr>
<td>ICU stay, days (±SD)</td>
<td>12.9 (23.8)</td>
</tr>
<tr>
<td>Hospital stay, days (±SD)</td>
<td>28.9 (32.7)</td>
</tr>
</tbody>
</table>

*Available for 203 patients.
ACE, angiotension-converting enzyme; AVV, atrioventricular valve; ECC, extracorporeal circulation; HTX, heart transplantation; ICU, intensive care unit; LV, left ventricle; NYHA, New York Heart Association; ns, not significant; RA, right atrial.

<table>
<thead>
<tr>
<th>Table 3</th>
<th>Indications for failing Fontan surgery</th>
</tr>
</thead>
<tbody>
<tr>
<td>Indication</td>
<td>Number (%)</td>
</tr>
<tr>
<td>Arrhythmia</td>
<td>98 (43.6)</td>
</tr>
<tr>
<td>Deteriorating functional class</td>
<td>97 (43.1)</td>
</tr>
<tr>
<td>Extreme RA dilatation</td>
<td>87 (38.7)</td>
</tr>
<tr>
<td>Obstruction</td>
<td>47 (20.9)</td>
</tr>
<tr>
<td>Protein losing enteropathy</td>
<td>31 (13.8)</td>
</tr>
<tr>
<td>Thrombus</td>
<td>26 (11.6)</td>
</tr>
<tr>
<td>AVV regurgitation</td>
<td>18 (8.0)</td>
</tr>
<tr>
<td>Pulmonary vein stenosis</td>
<td>11 (4.9)</td>
</tr>
<tr>
<td>Cyanosis</td>
<td>12 (5.3)</td>
</tr>
<tr>
<td>Systemic obstruction</td>
<td>4 (1.8)</td>
</tr>
<tr>
<td>Baffle leak</td>
<td>4 (1.8)</td>
</tr>
</tbody>
</table>

AVV, atrioventricular valve; RA, right atrial.

Figure 2  Indications for failing Fontan surgery. More than one indication is possible within the same patient. RA, right atrial; AVV, atrioventricular valve; PV, pulmonary vein; PLE, protein losing enteropathy; FC, functional class.
comparison between the two latter strategies, no survival benefit could be identified, yet we have to realise that these groups are selected for severity of ventricular dysfunction. Generally, the ventricular function was much poorer in the HTX group as compared with the conversion group. Furthermore, a valve-containing conduit is a risk factor for Fontan conversion in patients with APC with a failing Fontan circulation, the reason of which is currently subject to speculation.

Although survival has improved markedly in the past decades, Fontan patients are still at substantially increased risk of late morbidity and death as compared with the normal population. Presumably, the adult numbers of Fontan patients will increase by over 60% in the next decade and the proportion in NYHA FC III is expected to double. Unfortunately, a failing Fontan circulation represents a particularly complicated scenario for both patients and physicians. They are confronted with an insidiously deteriorating clinical situation, while there are no studies available that describe and compare treatment options. Given the overall young age of this population with impaired life expectancy, it is to be expected that a huge proportion of these patients will be candidates for failing Fontan surgery. In the current study, the complex nature of failing Fontan was confirmed since 65% of the failing Fontan patients had at least two indications that led to the decision to operate.

The current study demonstrated that Fontan takedown has primary been used as a bailout option in early Fontan failure, considering the short interval between Fontan completion and takedown surgery (ie, 7.2 months). This is in line with previous small case series (n ≤ 6), where Fontan takedown was accomplished in the early aftermath of Fontan completion. The different characteristics of the Fontan takedown population (‘early failing Fontan’) precludes a fair comparison with Fontan conversion or HTX (‘late failing Fontan’) and therefore we reported the outcome of this strategy separately. Our data showed that mortality rates are very high (40% after a mean follow-up of 6.7 years), especially in the first 30 days after Fontan takedown. Yet, the relative percentage of Fontan takedowns steadily decreased over time. This probably points to improved patient selection on the road towards Fontan completion. Whether Fontan takedown is a reasonable alternative for HTX or Fontan conversion in late failing Fontan remains to be elucidated.

Since the pioneering work of Mavroudis et al, Fontan conversion to the more energy-efficient extracardiac connection with concomitant arrhythmia surgery is the standard for patients with APC, especially those with atrial tachyarrhythmias. In their own single-centre series including 111 Fontan conversions, an early mortality rate of 0.9% was reported, but percentages up to 13% are described. In our study, early mortality was 11%. Recently, a study in 39 patients following Fontan conversion reported 8 deaths (21%) after a mean follow-up of 6 years. With a slightly longer mean follow-up (of 7.7 years), the current study demonstrated a similar mortality rate of 21%.

We previously described the outcome after HTX in Fontan patients (n=61), also including patients who initially were treated with Fontan conversion or Fontan takedown. In the current study, using an intention-to-treat analysis, we showed that during a mean FU of 5.7 years 34% died. Early mortality

---

**Table 4** Univariate and multivariate analysis in failing Fontan patients (n=187)

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Univariate N (%)</th>
<th>p Value</th>
<th>Multivariate HR (95% CI)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interval Fontan completion-failing Fontan surgery (&lt;10 years)</td>
<td>26 (26.6)</td>
<td>0.049</td>
<td>ns</td>
<td></td>
</tr>
<tr>
<td>NYHA class III/IV</td>
<td>32 (35.6)</td>
<td>0.028</td>
<td>ns</td>
<td></td>
</tr>
<tr>
<td>Moderate/poor ventricular function</td>
<td>37 (36.6)</td>
<td>0.004</td>
<td>2.52 (1.26 to 5.03)</td>
<td>0.009</td>
</tr>
</tbody>
</table>

HTX, heart transplantation; NYHA, New York Heart Association; ns, not significant.

---

**Figure 3** Kaplan–Meier plot showing the event-free survival for patients with an atroventricular connection (APC)-type Fontan (n=130) according to the presence or absence of a valve-containing conduit. End points are mortality or heart transplantation. yrs, years.

**Figure 4** Kaplan–Meier plot showing the event-free survival after heart transplantation (HTX) (n=50) or Fontan conversion (n=137). Time of follow-up is truncated at 15 years. End points are mortality or (re-)HTX. FC, functional class; yrs, years.
was high (20%), but this is in accordance with an actuarial survival after HTX of 80% at 6 months in a large cohort derived from the Pediatric Heart Transplant Study database in the USA.

Perhaps the most compelling contribution of the current study is the possibility to compare outcomes of Fontan conversion and HTX. We now could provide evidence that survival between HTX and Fontan conversion does not significantly differ. Furthermore, we found that poor systemic ventricular function was a risk factor for death/HTX after failing Fontan surgery. Possibly, ventricular dysfunction is associated with poor general health status and high patient frailty in Fontan patients, which may affect survival after surgery. Finally, it appeared that valve-containing APCs are at increased risk for Fontan conversion. For patients with APC, there was no specific treatment benefit for Fontan conversion or HTX, but this finding needs to be interpreted cautiously due to the fact that within the 130 patients with an APC, 119 patients were treated with a Fontan conversion, while only 11 patients were treated with HTX. Nevertheless, these results may be of importance for future treatment algorithms in patients with failing Fontan.

Our findings should be evaluated in the context of several limitations. First of all, our study is limited by its observational cohort design, which may complicate the interpretation of the results, derived from four decades of data acquisition. Related to this point, decision making for the different procedures was based on the discretion of the treating physician(s) and not on certain treatment algorithms. The best way to control for treatment-selection bias is to conduct a randomised trial, but given the relatively rare syndrome of failing Fontan, the set up of such a trial is, unfortunately, an utopia. Hence, the three pathways are not mutually exclusive and we have to realise that the Fontan background is not identical for every patient (eg, conversion is not an option for patients following TCPC EC). Nevertheless, our dataset provides unique information on long-term outcomes. Second, in our study we evaluated the three most performed surgical treatments for failing Fontan. Despite encouraging results of other surgical interventions in the last years, for example, with ventricular assist devices, we analysed these alternatives not systematically. Finally, some variables that are known in clinical practice to have a profound effect on the choice of failing Fontan surgery (eg, the presence of systemic-to-pulmonary arterial or venous collateral flow, anthropomorphic characteristics of the patient and patient frailty) were not available for this analysis.

In conclusion, the syndrome of failing Fontan is the result of an inevitable and insidious attrition of the Fontan circulation. Fontan takedown has been used as a surgical strategy for a failing Fontan circulation in the early postoperative phase with high risk for mortality. There is no difference in survival after Fontan conversion or HTX. Hence, these groups are selected for ventricular dysfunction. In general, a late failing Fontan patient with a poor ventricular function is better off with an HTX, while a patient with preserved ventricular function can well be treated with conversion.

Author affiliations
1Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
2Department of Pediatric Cardiology, Beatrix Children’s Hospital, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
3Technical University, German Heart Center Munich, Munich, Germany
4Department of Congenital Heart Disease, Centre Chirurgical Marie Lannelogne, Paris, France
5Department of Cardiac Surgery, Catholic University Leuven, Leuven, Belgium
6Pediatric and Congenital Cardiovascular Surgery Unit, Department of Cardiac Thoracic and Vascular Sciences, University of Padova, Padua, Italy
7Department of Thoracic and Cardiovascular Surgery, Rikshospitalet, Oslo University Hospital, Oslo, Norway
8Johns Hopkins All Children’s Heart Institute, All Children’s Hospital and Florida Hospital for Children, Saint Petersburg, Tampa, and Orlando, Florida, USA
9Johns Hopkins University, Baltimore, Maryland, USA
10Hospital for Children and Adolescents; University of Helsinki, Helsinki, Finland
11Children’s Heart Centre, The Queen Silvia Children’s Hospital, Gothenburg, Sweden
12Clinic for Cardiovascular Surgery, University Hospital Zurich, Zurich, Switzerland
13Leiden University Medical Center, Leiden, The Netherlands
14Academic Medical Center, Amsterdam, The Netherlands
15Department of Cardio-Thoracic Surgery, University Hospital of Copenhagen, Copenhagen, Denmark
16National Institute of Cardiovascular Disease, Children’s Heart Centre Slovak Republic, Bratislava, Slovakia
17Department of Pediatric Cardiac Surgery, Children’s Heart Center, Motol University Hospital, Prague, Czech Republic
18Division of Cardiac Surgery, Cliniques Universitaires Saint-Luc, Brussels, Belgium
19National Heart Hospital Sofia, Sofia, Bulgaria
20Department of Cardiovascular Surgery, Center for Congenital Heart Surgery, University Hospital Bern, Bern, Switzerland
21German Pediatric Heart Centre, Asklepios Clinic Sant Augustin, Sant Augustin, Germany
22Department of Cardiothoracic Surgery, Hospital de Santa Marta, Lisbon, Portugal
23Department of Congenital and Paediatric Cardiac Surgery and Cardiology, Riuniti Hospital, Ancona, Italy
24Athens Heart Surgery Institute, Athens, Greece
25Department of Pediatric, Congenital Heart Surgery at IASO Children’s Hospital, Athens, Greece
26Department of cardiothoracic surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
27Dipartimento Medico-Chirurgico di Cardiologia Pediatrica, Ospedale Pediatrico Bambino Gesù, Roma, Italy

Twitter Follow Harald Lindberg at @Noharald and Tjak Ebes at @Jjarkebels

Contributors All authors included on the submitted paper fulfill the criteria of authorship: (1) substantial contributions to the acquisition of data; (2) drafting the work or revising it critically for important intellectual content; (3) final approval of the version published; (4) agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. In addition, IPHM, DW and TE made substantial contributions to the conception or design of the work and analysis or interpretation of data.

Competing interests None declared.

Ethics approval Local Institutional Review Boards.

Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement Unpublished data are available for further analysis for the whole author group by mutual agreement.

REFERENCES

Surgical options after Fontan failure

Joost P van Melle, Djoekie Wolff, Jürgen Hörer, Emre Belli, Bart Meyns, Massimo Padalino, Harald Lindberg, Jeffrey P Jacobs, Ilkka P Mattila, Håkan Berggren, Rolf M F Berger, Rene Prêtre, Mark G Hazekamp, Morten Helvind, Matej Nosál, Tomas Tlaskal, Jean Rubay, Stojan Lazarov, Alexander Kadner, Viktor Hraska, José Fragata, Marco Pozzi, George Sarris, Guido Michielon, Duccio di Carlo and Tjark Ebels

Heart published online April 13, 2016

Updated information and services can be found at:
http://heart.bmj.com/content/early/2016/04/13/heartjnl-2015-309235

References
This article cites 26 articles, 14 of which you can access for free at:
http://heart.bmj.com/content/early/2016/04/13/heartjnl-2015-309235
#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
- Congenital heart disease in adult patients (82)
- Epidemiology (3642)
- Drugs: cardiovascular system (8633)
- Interventional cardiology (2875)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/